Response Assessment Criteria and Their Applications in Lymphoma: Part 2.
| Autor: | Moghbel MC; Stanford University Medical Center, Stanford, California mateenm@stanford.edu., Mittra E; Stanford University Medical Center, Stanford, California., Gallamini A; Antoine Lacassagne Cancer Center, Nice University, Nice, France., Niederkohr R; Kaiser Permanente, Santa Clara, California., Chen DL; Washington University, St. Louis, Missouri., Zukotynski K; McMaster University, Hamilton, Ontario, Canada., Nadel H; University of British Columbia, Vancouver, British Columbia, Canada; and., Kostakoglu L; Mount Sinai Hospital, New York, New York. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Journal of nuclear medicine : official publication, Society of Nuclear Medicine [J Nucl Med] 2017 Jan; Vol. 58 (1), pp. 13-22. Date of Electronic Publication: 2016 Nov 22. |
| DOI: | 10.2967/jnumed.116.184242 |
| Abstrakt: | Interim and end-of-treatment PET/CT have become central to the evaluation of Hodgkin and non-Hodgkin lymphoma. This review article seeks to aid clinical decision making by providing an overview of available data on the diagnostic and prognostic value of PET/CT imaging for response assessment and pretransplant evaluation in lymphoma. The relative strengths and limitations of these techniques in various disease subtypes and clinical scenarios are explored, along with their current standards for reporting and latest developments. Particular attention is given to response-adapted therapy, which is emerging as a cornerstone of clinical management. (© 2017 by the Society of Nuclear Medicine and Molecular Imaging.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|